Gene: FZD2

2535
Fz2|fz-2|fzE2|hFz2
frizzled class receptor 2
protein-coding
17q21.31
Ensembl:ENSG00000180340 MIM:600667 Vega:OTTHUMG00000181819 UniprotKB:Q14332
NC_000017.11
PubMed
0   ANCO-SNPs
ND
1   
7.988e-1 (AD)  5.350e-1 (ND)   (Frontal_Cortex)
2.491e-1 (AD)  1.879e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SH3BP20.738
EMILIN10.71
LYN0.682
UNC93B10.674
DOK10.671
TMEM510.666
TRIM210.655
FGF110.652
NMI0.65
PRICKLE30.65

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
BFSP1-0.415
ADTRP-0.414
AGBL4-0.41
KCNB2-0.408
PPEF1-0.406
TMEFF2-0.403
BAAT-0.403
ATOH7-0.393
SLC7A4-0.391
ROPN1L-0.39

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FZD2 mRNA28329830
C0299552-nitrotoluene2-nitrotoluene results in decreased expression of FZD2 mRNA16460773
C4727913-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in decreased expression of FZD2 mRNA16788091
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C517041(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)"(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in decreased expression of FZD2 mRNA"19561079
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of FZD2 gene27153756
C010845aluminum chloridealuminum chloride results in decreased activity of FZD2 protein26474975
C010845aluminum chloridealuminum chloride results in decreased expression of FZD2 mRNA26474975
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FZD2 mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of FZD2 mRNA24449571
D001205Ascorbic Acid[Quercetin co-treated with Ascorbic Acid] results in increased expression of FZD2 mRNA17639512
C547126AZM551248AZM551248 results in increased expression of FZD2 mRNA22323515
D001564Benzo(a)pyreneAHR protein inhibits the reaction [Benzo(a)pyrene results in decreased expression of FZD2 mRNA]15034205
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FZD2 mRNA15034205
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FZD2 mRNA21839799
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of FZD2 mRNA"20382639
D004958EstradiolEstradiol affects the expression of FZD2 mRNA14699072
C044887beta-methylcholinebeta-methylcholine affects the expression of FZD2 mRNA21179406
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of FZD2 mRNA28628672
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FZD2 mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of FZD2 mRNA24465770
C006780bisphenol A[potassium bromate co-treated with bisphenol A] affects the expression of FZD2 mRNA27082013
C006780bisphenol A[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of FZD2 mRNA]27082013
C006780bisphenol Abisphenol A affects the expression of FZD2 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FZD2 mRNA28628672
D000069286Bortezomib[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA25522274
C099813bromochloroacetic acidbromochloroacetic acid results in decreased expression of FZD2 mRNA16460773
D002104CadmiumCadmium results in decreased expression of FZD2 mRNA23369406
D019256Cadmium ChlorideCadmium Chloride results in increased expression of FZD2 mRNA20478370
D002220CarbamazepineCarbamazepine affects the expression of FZD2 mRNA25979313
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of FZD2 mRNA17484886
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of FZD2 mRNA16780995
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of FZD2 mRNA26272509
D002737ChloropreneChloroprene results in decreased expression of FZD2 mRNA23125180
C012843cinnamic aldehydecinnamic aldehyde results in increased expression of FZD2 mRNA17178418
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in decreased expression of FZD2 mRNA19167446
D016572CyclosporineCyclosporine results in increased expression of FZD2 mRNA20106945
C014347decitabinedecitabine results in increased expression of FZD2 mRNA27915011
D003907DexamethasoneDexamethasone results in decreased expression of FZD2 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of FZD2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FZD2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FZD2 mRNA28628672
D003907Dexamethasone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA16054899
D003907DexamethasoneEGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
D003907DexamethasoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of FZD2 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of FZD2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of FZD2 mRNA27392435
D004026DieldrinDieldrin results in increased expression of FZD2 mRNA19130878
C058705diethyl malatediethyl malate affects the expression of FZD2 mRNA24814887
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of FZD2 mRNA15766595
C118739entinostatentinostat results in decreased expression of FZD2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FZD2 mRNA22079256
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FZD2 mRNA28329830
C007738fluoranthenefluoranthene results in decreased expression of FZD2 mRNA28329830
D005472FluorouracilFZD2 protein affects the susceptibility to Fluorouracil16217747
C069837fullerene C60fullerene C60 results in increased expression of FZD2 mRNA19167457
C039281furanfuran results in decreased methylation of FZD2 gene27387713
C039281furanfuran results in increased expression of FZD2 mRNA27387713
D017313FenretinideFenretinide results in decreased expression of FZD2 mRNA28973697
D017313FenretinideFenretinide results in increased expression of FZD2 mRNA28973697
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of FZD2 mRNA20044591
C492448ICG 001ICG 001 results in decreased expression of FZD2 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of FZD2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FZD2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FZD2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of FZD2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FZD2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of FZD2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA16054899
D0150561-Methyl-3-isobutylxanthineEGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
D0150561-Methyl-3-isobutylxanthineTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of FZD2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of FZD2 mRNA26830473
D008627Mercuric ChlorideMercuric Chloride affects the expression of FZD2 mRNA20353558
D008727MethotrexateMethotrexate results in decreased expression of FZD2 mRNA17379860
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FZD2 mRNA28001369
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of FZD2 mRNA"20188158
D008942MitoxantroneFZD2 protein affects the susceptibility to Mitoxantrone16217747
C028007nickel monoxidenickel monoxide results in increased expression of FZD2 mRNA19167457
C029938nickel sulfatenickel sulfate results in decreased expression of FZD2 mRNA16100012|1616674
D009534NiclosamideNiclosamide results in decreased expression of FZD2 mRNA22576131
D010126OzoneOzone results in decreased expression of FZD2 mRNA17460151
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of FZD2 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of FZD2 mRNA26272509
D010705PhosgenePhosgene affects the expression of FZD2 mRNA16300373
D010852PicrotoxinPicrotoxin results in increased expression of FZD2 mRNA15170462
C019536potassium bromate[potassium bromate co-treated with bisphenol A] affects the expression of FZD2 mRNA27082013
C019536potassium bromate[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of FZD2 mRNA]27082013
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FZD2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of FZD2 mRNA22079256
D011441PropylthiouracilPropylthiouracil results in increased expression of FZD2 mRNA24780913
C010313pseudocumenepseudocumene results in decreased expression of FZD2 protein17337753
C513428pyrachlostrobinpyrachlostrobin results in increased expression of FZD2 mRNA27029645
D011794Quercetin[Quercetin co-treated with Ascorbic Acid] results in increased expression of FZD2 mRNA17639512
C059514resveratrol[Coumestrol co-treated with resveratrol] results in decreased expression of FZD2 mRNA19167446
C089730rosiglitazone[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA16054899
C089730rosiglitazoneEGF protein inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
C089730rosiglitazoneTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
C010327salinomycinsalinomycin results in decreased expression of FZD2 mRNA19682730
D019821SimvastatinSimvastatin results in increased expression of FZD2 mRNA19968183
C009277sodium arsenatesodium arsenate results in decreased expression of FZD2 mRNA21795629
C017947sodium arseniteTP53 protein affects the reaction [sodium arsenite results in increased expression of FZD2 mRNA]16966095
D012999SomanSoman results in decreased expression of FZD2 mRNA19281266
D013629TamoxifenTamoxifen results in increased expression of FZD2 mRNA25123088
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of FZD2 mRNA25172293
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FZD2 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FZD2 mRNA]16054899
D013849ThimerosalThimerosal results in decreased expression of FZD2 mRNA27188386
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of FZD2 mRNA28065790
D014212TretinoinTretinoin results in decreased expression of FZD2 mRNA20530235
D014212TretinoinTretinoin results in decreased expression of FZD2 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of FZD2 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FZD2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of FZD2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of FZD2 mRNA17292431
D000068756ValsartanValsartan inhibits the reaction [AGT protein results in decreased expression of FZD2 mRNA]19225232
C100058vanillinvanillin results in decreased expression of FZD2 mRNA17178418
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of FZD2 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25417160  
GO:0017147Wnt-protein binding-IBA21873635  
GO:0017147Wnt-protein binding-NAS24431302  
GO:0030165PDZ domain binding-IPI19388021  
GO:0042813Wnt-activated receptor activity-IBA21873635  
GO:0042813Wnt-activated receptor activity-IDA28733458  
GO:0042813Wnt-activated receptor activity-NAS24431302  
GO ID GO Term Qualifier Evidence PubMed
GO:0003149membranous septum morphogenesis-IEA-  
GO:0003150muscular septum morphogenesis-IEA-  
GO:0003151outflow tract morphogenesis-IEA-  
GO:0007186G-protein coupled receptor signaling pathway-IEA-  
GO:0007223Wnt signaling pathway, calcium modulating pathway-TAS-  
GO:0007608sensory perception of smell-IEA-  
GO:0030182neuron differentiation-ISS-  
GO:0030855epithelial cell differentiation-IEA-  
GO:0035567non-canonical Wnt signaling pathway-IBA21873635  
GO:0045893positive regulation of transcription, DNA-templated-IDA18215320  18929644  
GO:0051091positive regulation of DNA-binding transcription factor activity-IDA18929644  
GO:0060022hard palate development-IEA-  
GO:0060070canonical Wnt signaling pathway-IBA21873635  
GO:0060070canonical Wnt signaling pathway-IDA18215320  18929644  20802536  28733458  
GO:0060071Wnt signaling pathway, planar cell polarity pathway-NAS24431302  
GO:0060071Wnt signaling pathway, planar cell polarity pathway-TAS-  
GO:0060119inner ear receptor cell development-IEA-  
GO:0090103cochlea morphogenesis-IEA-  
GO:0090179planar cell polarity pathway involved in neural tube closure-IEA-  
GO:1904886beta-catenin destruction complex disassembly-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IDA19038973  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-IDA18929644  
GO:0005886plasma membrane-TAS-  
GO:0005925focal adhesion-HDA21423176  
GO:0016021integral component of membrane-IBA21873635  
GO:0030669clathrin-coated endocytic vesicle membrane-TAS-  
KEGG ID KEGG Term
hsa04310Wnt signaling pathway
hsa04916Melanogenesis
hsa05200Pathways in cancer
hsa05217Basal cell carcinoma
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-195721Signaling by WNTTAS
R-HSA-195721Signaling by WNTIEA
R-HSA-201681TCF dependent signaling in response to WNTTAS
R-HSA-201681TCF dependent signaling in response to WNTIEA
R-HSA-372790Signaling by GPCRIEA
R-HSA-373080Class B/2 (Secretin family receptors)IEA
R-HSA-3858494Beta-catenin independent WNT signalingTAS
R-HSA-3858494Beta-catenin independent WNT signalingIEA
R-HSA-4086398Ca2+ pathwayTAS
R-HSA-4086398Ca2+ pathwayIEA
R-HSA-4086400PCP/CE pathwayTAS
R-HSA-4608870Asymmetric localization of PCP proteinsTAS
R-HSA-4641262Disassembly of the destruction complex and recruitment of AXIN to the membraneTAS
R-HSA-4641262Disassembly of the destruction complex and recruitment of AXIN to the membraneIEA
R-HSA-500792GPCR ligand bindingIEA
R-HSA-5140745WNT5A-dependent internalization of FZD2, FZD5 and ROR2TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23370438Role of aberrant WNT signalling in the airway epithelial response to cigarette smoke in chronic obstructive pulmonary disease. (2013 Aug)Heijink IHThorax